Key result
Esomeprazole 20 mg once daily reduced the risk of gastric or duodenal ulcers compared to placebo (1.8% vs 6.2%; P=0.0007) in patients aged >=60 years on continuous low-dose aspirin.
Why the study?
Does esomeprazole 20 mg once daily reduce the risk of gastroduodenal ulcers in patients aged >= 60 years receiving continuous low-dose aspirin?
RCT (n=991)
randomized
Does esomeprazole 20 mg once daily reduce the risk of gastroduodenal ulcers in patients aged >= 60 years receiving continuous low-dose aspirin?
Absolute Event Rate: 1.8% vs 6.2%
p-value: p=0.0007
Esomeprazole 20 mg once daily significantly reduces the risk of developing gastric and/or duodenal ulcers and upper GI symptoms in older patients on continuous low-dose aspirin.
No takes yet. Share an insight, caveat, or question.
Esomeprazole reduces ulcer risk in elderly aspirin users; supports routine gastroprotection and confirms PPI efficacy in this RCT population.
Yeomans et al. (2008) conducted an RCT in Continuous use of low-dose aspirin (n=991). Esomeprazole vs. Placebo was evaluated on Development of a gastric or duodenal ulcer (p=0.0007). Esomeprazole 20 mg once daily reduced the risk of gastric or duodenal ulcers compared to placebo (1.8% vs 6.2%; P=0.0007) in patients aged >=60 years on continuous low-dose aspirin.